Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Jaina Patel was in her early 30s when a bout of bronchitis led to hear losing weight, her job and eventually her sense of ...

Dupilumab significantly improved asthma control and quality of life among children aged 6 to 11 years with uncontrolled moderate to severe asthma, researchers reported at the virtual European ...

Source Reference: Lugogo NL, et al "Characterization of patients with asthma treated with dupilumab in a real-world setting: The RAPID registry" CHEST 2022; DOI: 10.1016/j.chest.2022.08.2185.

The new study was funded by Sanofi and Regeneron Pharmaceuticals, which make dupilumab. Asthma is the most common chronic disorder of childhood and affects more than 5 million children younger ...

Dupilumab was shown to consistently reduce the risk of serious asthma exacerbations, improve lung function, and reduce Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) score ...

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma ...

Better asthma control, as indicated by lower mean scores on the Asthma Control Questionnaire-5, were seen in both the dupilumab and placebo groups. SEATTLE — Asthma control, as measured by the 5 ...

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the ...

Key takeaways: Asthma exacerbation rates ranged from 0.91 to 1.37 for the placebo group and from 0.32 to 0.58 for the dupilumab group. Exacerbations peaked in winter with placebo and in autumn ...

Moreover, the proportion of patients with dupilumab who experienced 1 or more severe asthma exacerbation compared with placebo was 10% vs 20.8% in spring, 7.3% vs 18.2% in summer, 12.6% vs 22.2% ...

Dupixent ® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial Data ...